JP2023537403A5 - - Google Patents
Info
- Publication number
- JP2023537403A5 JP2023537403A5 JP2023509723A JP2023509723A JP2023537403A5 JP 2023537403 A5 JP2023537403 A5 JP 2023537403A5 JP 2023509723 A JP2023509723 A JP 2023509723A JP 2023509723 A JP2023509723 A JP 2023509723A JP 2023537403 A5 JP2023537403 A5 JP 2023537403A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- mtx
- pegylated uricase
- uricase
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063826P | 2020-08-10 | 2020-08-10 | |
| US63/063,826 | 2020-08-10 | ||
| US202163148982P | 2021-02-12 | 2021-02-12 | |
| US63/148,982 | 2021-02-12 | ||
| PCT/US2021/045350 WO2022035828A1 (en) | 2020-08-10 | 2021-08-10 | Methods of treating gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537403A JP2023537403A (ja) | 2023-08-31 |
| JP2023537403A5 true JP2023537403A5 (https=) | 2024-08-20 |
Family
ID=80247297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509723A Pending JP2023537403A (ja) | 2020-08-10 | 2021-08-10 | 痛風を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230301999A1 (https=) |
| EP (2) | EP4588513A3 (https=) |
| JP (1) | JP2023537403A (https=) |
| KR (1) | KR20230086660A (https=) |
| CN (1) | CN116261463A (https=) |
| AU (1) | AU2021324665A1 (https=) |
| BR (1) | BR112023002458A2 (https=) |
| CA (1) | CA3189100A1 (https=) |
| IL (1) | IL300536A (https=) |
| MX (1) | MX2023001740A (https=) |
| WO (1) | WO2022035828A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG161247A1 (en) | 2005-04-11 | 2010-05-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| WO2020160322A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| EP4588513A3 (en) * | 2020-08-10 | 2025-10-22 | Horizon Therapeutics USA, Inc. | Methods of treating gout |
| WO2024088213A1 (en) * | 2022-10-24 | 2024-05-02 | Westlake Therapeutics (Shanghai) Co., Limited | Combination to induce specific immune tolerance |
| US12201413B2 (en) | 2023-03-01 | 2025-01-21 | Washington University | Free breathing dynamic contrast enhanced (DCE) liver MR imaging |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE498409T1 (de) | 1998-08-06 | 2011-03-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| WO2000008196A2 (en) * | 1998-08-06 | 2000-02-17 | Duke University | Urate oxidase |
| MX2007012548A (es) | 2005-04-11 | 2008-03-11 | Savient Pharmaceuticals Inc | Formas variantes de urato oxidasa y uso de las mismas. |
| SG161247A1 (en) | 2005-04-11 | 2010-05-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| JP5033177B2 (ja) | 2006-04-12 | 2012-09-26 | サビエント ファーマセウティカルズ インク． | 陽イオン界面活性剤によるタンパク質の精製 |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| KR20180120753A (ko) * | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| ES3036482T3 (en) * | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2020160325A1 (en) * | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2020160324A1 (en) * | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| EP4588513A3 (en) * | 2020-08-10 | 2025-10-22 | Horizon Therapeutics USA, Inc. | Methods of treating gout |
-
2021
- 2021-08-10 EP EP25163173.5A patent/EP4588513A3/en active Pending
- 2021-08-10 CA CA3189100A patent/CA3189100A1/en active Pending
- 2021-08-10 WO PCT/US2021/045350 patent/WO2022035828A1/en not_active Ceased
- 2021-08-10 KR KR1020237008344A patent/KR20230086660A/ko active Pending
- 2021-08-10 JP JP2023509723A patent/JP2023537403A/ja active Pending
- 2021-08-10 MX MX2023001740A patent/MX2023001740A/es unknown
- 2021-08-10 US US18/020,761 patent/US20230301999A1/en active Pending
- 2021-08-10 IL IL300536A patent/IL300536A/en unknown
- 2021-08-10 EP EP21856554.7A patent/EP4192581A4/en not_active Withdrawn
- 2021-08-10 BR BR112023002458A patent/BR112023002458A2/pt unknown
- 2021-08-10 AU AU2021324665A patent/AU2021324665A1/en active Pending
- 2021-08-10 CN CN202180053221.3A patent/CN116261463A/zh active Pending
-
2022
- 2022-02-09 US US17/668,015 patent/US20220323445A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537403A5 (https=) | ||
| EP3272342B1 (en) | Methods and compositions for treatment of attention deficit disorder | |
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP2002510612A (ja) | 健康および安寧の向上のために使用される物質の効力の最大化 | |
| KR20200010320A (ko) | 치료 방법 | |
| JP2025013854A (ja) | Ｐｄｅ－５阻害剤と吸入用一酸化窒素との併用薬物療法 | |
| KR19990082429A (ko) | 장염 질환을 치료하기 위한 니코틴의 결장 전달 | |
| EP3630763A1 (en) | Corticotropin releasing factor receptor antagonists | |
| RU2010135831A (ru) | Способы, лекарственные формы и наборы для введения зипрасидона без пищи | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| JP2023501457A5 (https=) | ||
| JP4896334B2 (ja) | 睡眠時呼吸障害を治療及び診断する方法並びにその方法を実施する手段 | |
| JP2022075670A (ja) | ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬 | |
| CN120478602A (zh) | 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 | |
| Canny et al. | Does ketotifen have a steroid-sparing effect in childhood asthma? | |
| US20070105817A1 (en) | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension | |
| JP7738832B2 (ja) | 低亜鉛血症治療剤 | |
| RU2023105050A (ru) | Способы лечения подагры | |
| JP6420923B1 (ja) | 医薬 | |
| CN116157119A (zh) | 一种ARNi与钙离子拮抗剂的药物组合物与应用 | |
| CN120641130A (zh) | (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗类风湿性关节炎中的用途 | |
| CN102274160B (zh) | 用于治疗对抗高血压药的抗药性和相关病症的方法和制剂 | |
| EP1323432B1 (en) | Complexes of cyclodextrins with potassium ion homeostasis regulators | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| WO2026052723A1 (en) | Givinostat hydrochloride monohydrate for use in treating muscular dystrophy |